Philip Denniff1, Neil Spooner. 1. Platform Technology & Science, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Research & Development, Ware, Hertfordshire, SG12 0DP, UK. philip_denniff-1@gsk.com
Abstract
BACKGROUND: As hematocrit levels are known to vary between individuals and with disease state, its effect on the physical characteristics of dried blood spot (DBS) samples and on the accurate quantification of analytes within these samples is examined. RESULTS: The area of DBS samples decreases with increasing hematocrit levels in a linear manner on the three cellulose paper substrates tested. Furthermore, a bias was observed in the concentrations of two analytes determined in DBS samples at different hematocrits, which in some cases exceeded acceptable values, particularly for hematocrits outside normal values. CONCLUSION: If it is expected that the hematocrit of study samples will vary from values considered normal, then its effect on the quantitative determination of an analyte in DBS samples should be investigated as part of the method development and validation. If an unacceptable effect is observed, then this will need to be addressed, by modification of the analytical method, or the inclusion of quality control samples at different hematocrit levels to show control of the assay.
BACKGROUND: As hematocrit levels are known to vary between individuals and with disease state, its effect on the physical characteristics of dried blood spot (DBS) samples and on the accurate quantification of analytes within these samples is examined. RESULTS: The area of DBS samples decreases with increasing hematocrit levels in a linear manner on the three cellulose paper substrates tested. Furthermore, a bias was observed in the concentrations of two analytes determined in DBS samples at different hematocrits, which in some cases exceeded acceptable values, particularly for hematocrits outside normal values. CONCLUSION: If it is expected that the hematocrit of study samples will vary from values considered normal, then its effect on the quantitative determination of an analyte in DBS samples should be investigated as part of the method development and validation. If an unacceptable effect is observed, then this will need to be addressed, by modification of the analytical method, or the inclusion of quality control samples at different hematocrit levels to show control of the assay.
Authors: Rebecca L Shaner; Nicholas D Schulze; Craig Seymour; Elizabeth I Hamelin; Jerry D Thomas; Rudolph C Johnson Journal: Anal Methods Date: 2017-06-16 Impact factor: 2.896
Authors: Christopher Evans; Mark Arnold; Peter Bryan; Jeffrey Duggan; Christopher A James; Wenkui Li; Steve Lowes; Luca Matassa; Timothy Olah; Philip Timmerman; Xiaomin Wang; Enaksha Wickremsinhe; John Williams; Eric Woolf; Patricia Zane Journal: AAPS J Date: 2014-12-09 Impact factor: 4.009
Authors: Joseph E Rower; David J Anderson; Catherine M Sherwin; Christopher A Reilly; Philip L Ballard; Cindy T McEvoy; Diana G Wilkins Journal: J Pharm Biomed Anal Date: 2019-01-29 Impact factor: 3.935
Authors: Rebecca L Shaner; Rebecca M Coleman; Nicholas Schulze; Kelsey Platanitis; Ashli A Brown; Craig Seymour; Pearl Kaplan; Jonas Perez; Elizabeth I Hamelin; Rudolph C Johnson Journal: Anal Chim Acta Date: 2018-06-20 Impact factor: 6.558
Authors: Jonas W Perez; Brooke G Pantazides; Caroline M Watson; Jerry D Thomas; Thomas A Blake; Rudolph C Johnson Journal: Anal Chem Date: 2015-05-20 Impact factor: 6.986